A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

NCT06674577 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

476

Enrollment

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy (IgAN)
Renal and Urinary Disorders
Berger Disease

Interventions

DRUG: Atacicept 150 mg

Sponsor

Vera Therapeutics, Inc.